2000
Serum and Urinary Prostate-specific Antigen and Urinary Human Glandular Kallikrein Concentrations Are Significantly Increased after Testosterone Administration in Female-to-Male Transsexuals
Obiezu C, Giltay E, Magklara A, Scorilas A, Gooren L, Yu H, Howarth D, Diamandis E. Serum and Urinary Prostate-specific Antigen and Urinary Human Glandular Kallikrein Concentrations Are Significantly Increased after Testosterone Administration in Female-to-Male Transsexuals. Clinical Chemistry 2000, 46: 859-862. PMID: 10839777, DOI: 10.1093/clinchem/46.6.859.Peer-Reviewed Original ResearchConceptsUrinary prostate specific antigenProstate-specific antigenTestosterone administrationSerum prostate-specific antigenMale transsexualsMonths of treatmentMonths post treatmentHK2 concentrationsSerum hK2Testosterone treatmentAndrogen administrationAndrogenic stimulationKallikrein concentrationImmunofluorometric methodTime pointsHK2AdministrationMonthsWomenTreatmentPost treatmentAntigenCultured cellsFemalesCorresponding mean valuesRelapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up
Vassilikos E, Yu H, Trachtenberg J, Nam R, Narod S, Bromberg I, Diamandis E. Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. Clinical Biochemistry 2000, 33: 115-123. PMID: 10751589, DOI: 10.1016/s0009-9120(99)00099-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedDisease-Free SurvivalFluorescent Antibody TechniqueFollow-Up StudiesHumansMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingProportional Hazards ModelsProstatectomyProstate-Specific AntigenProstatic NeoplasmsRecurrenceRegression AnalysisReproducibility of ResultsSensitivity and SpecificityTime FactorsTreatment OutcomeConceptsProstate cancer patientsRadical prostatectomySerum PSACancer patientsPSA assaysUltrasensitive prostate specific antigenPre-operative PSAGroup of patientsSerial serum samplesEarly therapeutic interventionSeminal vesicle invasionSurgical margin positivityProstate-specific antigenRegular PSAUltrasensitive PSAPSA increaseMargin positivityClinical stageGleason scorePrognostic indicatorCapsular invasionTissue involvementTumor volumePatientsFast relapseDRAMATIC SUPPRESSION OF PLASMA AND URINARY PROSTATE SPECIFIC ANTIGEN AND HUMAN GLANDULAR KALLIKREIN BY ANTIANDROGENS IN MALE-TO-FEMALE TRANSSEXUALS
OBIEZU C, GILTAY E, MAGKLARA A, SCORILAS A, GOOREN L, YU H, DIAMANDIS E. DRAMATIC SUPPRESSION OF PLASMA AND URINARY PROSTATE SPECIFIC ANTIGEN AND HUMAN GLANDULAR KALLIKREIN BY ANTIANDROGENS IN MALE-TO-FEMALE TRANSSEXUALS. Journal Of Urology 2000, 163: 802. DOI: 10.1097/00005392-200003000-00023.Peer-Reviewed Original ResearchUrinary prostate specific antigenProstate-specific antigenCyproterone acetateHormonal therapySpecific antigenFemale transsexualsSensitive immunofluorometric procedureUrine samplesMonths of therapyMonths of treatmentInitiation of treatmentCyproterone acetate therapyProstate cancer treatmentHK2 concentrationsTransdermal estradiolAcetate therapyTumor burdenAntiandrogen treatmentSteroidal antiandrogenAndrogen receptorProstate cancerEthinyl estradiolStudy groupPatient's bloodTherapy successClinical implications of prostate-specific antigen in men and women.
Yu H. Clinical implications of prostate-specific antigen in men and women. Journal Of Gender-Specific Medicine 2000, 3: 45-8, 53. PMID: 11253246.Peer-Reviewed Original ResearchConceptsProstate-specific antigenPresence of PSAClinical implicationsLevels of PSABreast tissueBreast cancer patientsBreast cancer riskSex steroid hormonesValuable tumor markerExcess androgenFavorable prognosisPregnant womenBreast fluidCancer patientsNipple aspiratesProstate cancerClinical studiesCancer riskTumor markersCyst fluidFemale serumSteroid hormonesConcentration of PSAMore studiesWomen
1999
Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination
Yu H, Levesque M, Clark G, Diamandis E. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. British Journal Of Cancer 1999, 81: 490-495. PMID: 10507775, PMCID: PMC2362935, DOI: 10.1038/sj.bjc.6690720.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsBiomarkers, TumorBreast NeoplasmsCarcinomaChemotherapy, AdjuvantCombined Modality TherapyDisease-Free SurvivalDNA ReplicationEnzyme-Linked Immunosorbent AssayFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticGenes, p53HumansLife TablesLymphatic MetastasisMastectomyMultivariate AnalysisNeoplasm ProteinsNeoplasm Recurrence, LocalNeoplasms, Hormone-DependentPloidiesPrognosisProportional Hazards ModelsProstate-Specific AntigenRadiotherapy, AdjuvantReceptors, EstrogenReceptors, ProgesteroneRiskSensitivity and SpecificitySurvival AnalysisSurvival RateTreatment OutcomeTumor Suppressor Protein p53ConceptsEnzyme-linked immunosorbent assayDisease-free survivalBreast cancer patientsCancer patientsRelative riskCox proportional hazards regression analysisProstate-specific antigen expressionProportional hazards regression analysisReceipt of chemotherapyProgesterone receptor statusSteroid hormone receptor analysisHazards regression analysisRecent clinical evidenceLog-rank testKaplan-Meier plotsOverall survival probabilityHormone receptor analysisPrimary breast carcinomaQuantitative enzyme-linked immunosorbent assayProstate-specific antigenP53 expression statusAssessment of p53Breast cancer prognosisS-phase fractionExpression of p53Prostate-specific antigen (PSA) in women.
Yu H, Berkel H. Prostate-specific antigen (PSA) in women. Journal Of The Louisiana State Medical Society 1999, 151: 209-13. PMID: 10234897.Peer-Reviewed Original ResearchConceptsProstate-specific antigenBreast cancerPSA levelsProduction of PSABetter disease-free survivalSerum prostate-specific antigenBreast tissueDisease-free survivalBreast cancer riskValuable tumor markerExcess androgenOverall survivalGestational agePregnant womenBreast fluidProgesterone receptorMenstrual cycleNipple aspiratesProstate cancerClinical studiesEstrogen receptorCancer riskTumor markersCyst fluidAmniotic fluidSeminal plasma biochemical markers and their association with semen analysis findings
Diamandis E, Arnett W, Foussias G, Pappas H, Ghandi S, Melegos D, Mullen B, Yu H, Srigley J, Jarvi K. Seminal plasma biochemical markers and their association with semen analysis findings. Urology 1999, 53: 596-603. PMID: 10096390, DOI: 10.1016/s0090-4295(98)00550-0.Peer-Reviewed Original ResearchConceptsVasectomy patientsProstaglandin D synthaseDifferential diagnosisBiochemical markersInsulin-like growth factorPlasma biochemical markersProstate-specific antigenSemen analysis findingsPercentage of motilityPGDS concentrationSeminal plasmaNormal morphologySperm qualitySeminal plasma correlatesPatient ageClinical valueNormal subjectsNonobstructive azoospermiaPatientsClinical groupsBiochemical parametersPlasma correlateProtein 3Immunofluorometric procedureGrowth factorPrognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma
Diamandis E, Helle S, Yu H, Melegos D, Lundgren S, Lonning P. Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma. Cancer 1999, 85: 891-898. PMID: 10091767, DOI: 10.1002/(sici)1097-0142(19990215)85:4<891::aid-cncr17>3.0.co;2-k.Peer-Reviewed Original ResearchConceptsPlasma prostate-specific antigenProstate-specific antigenPlasma PSA levelsMetastatic breast carcinomaMegestrol acetatePSA levelsPSA increaseMA treatmentPrognostic valueBreast carcinomaSpecific antigenSecretion of PSAMegestrol acetate treatmentPlasma PSA concentrationProgestin megestrol acetateSensitive immunofluorometric procedureSerial plasma levelsSubset of patientsOverall patient survivalRisk of deathMA withdrawalAlternative regimensPSA changeBetter prognosisDistant metastasisExpression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer
Foekens J, Diamandis E, Yu H, Look M, Gelder M, Putten W, Klijn J. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. British Journal Of Cancer 1999, 79: 888-894. PMID: 10070886, PMCID: PMC2362687, DOI: 10.1038/sj.bjc.6690142.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, HormonalBreast NeoplasmsCombined Modality TherapyDisease-Free SurvivalFemaleFollow-Up StudiesHumansLymphatic MetastasisMiddle AgedNeoplasm StagingPostmenopausePredictive Value of TestsPremenopauseProstate-Specific AntigenReceptors, EstrogenReceptors, ProgesteroneRetrospective StudiesSurvival AnalysisTamoxifenTime FactorsConceptsLevels of PSAProstate-specific antigenPrimary breast cancerRecurrent breast cancerBreast tumor cytosolsBreast cancerRecurrent diseaseEnzyme-linked immunosorbent assayTamoxifen therapyPoor responseTumor cytosolsAge/menopausal statusFirst-line tamoxifen therapyHormone receptor-negative tumorsSteroid hormone receptor statusDisease-free intervalSite of relapseCox multivariate analysisHormone receptor statusReceptor-negative tumorsClassical prognostic factorsPost-menopausal patientsRate of relapseBreast cancer patientsStart of treatment
1998
Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study.
Yu H, Levesque M, Clark G, Diamandis E. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clinical Cancer Research 1998, 4: 1489-97. PMID: 9626467.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnalysis of VarianceBiomarkers, TumorBreast NeoplasmsCohort StudiesCytosolFemaleFollow-Up StudiesHumansLymphatic MetastasisMiddle AgedPloidiesPrognosisProstate-Specific AntigenReceptors, EstrogenReceptors, ProgesteroneS PhaseSurvival AnalysisTime FactorsUnited StatesConceptsProstate-specific antigenPrimary breast cancerBreast cancerCohort studyPrognostic valueRelative riskBreast tumorsSteroid hormone receptor levelsLow S-phase fractionMeasurement of PSAPSA-negative patientsPSA-positive patientsPrognosis of patientsYounger patient ageHormone receptor levelsLarge cohort studyUnited States cohort studyValuable tumor markerS-phase fractionUnited States patientsBreast tumor extractsMedian followPSA presenceNodal statusPatient age
1997
NONPROSTATIC SOURCES OF PROSTATE-SPECIFIC ANTIGEN
Diamandis E, Yu H. NONPROSTATIC SOURCES OF PROSTATE-SPECIFIC ANTIGEN. Urologic Clinics Of North America 1997, 24: 275-282. PMID: 9126224, DOI: 10.1016/s0094-0143(05)70373-6.Peer-Reviewed Original ResearchConceptsNonprostatic tissuesProstate-specific antigenBreast nipple aspirate fluidBreast cancer risk assessmentPSA gene expressionBreast cancer cytosolsHigher PSA concentrationsBreast cancer prognosisRegulation of PSAPotential clinical utilityCancer risk assessmentMicrograms/LNonprostatic sourcesPSA regulationAndrogen excessSerum PSAMicrograms/L.Breast secretionsAspirate fluidSeminal plasmaPSA productionPSA-ACT complexClinical utilityCancer cytosolsProstatic tissueProstate-Specific Antigen in Female Serum, a Potential New Marker of Androgen Excess
Melegos D, Yu H, Ashok M, Wang C, Stanczyk F, Diamandis E. Prostate-Specific Antigen in Female Serum, a Potential New Marker of Androgen Excess. The Journal Of Clinical Endocrinology & Metabolism 1997, 82: 777-780. PMID: 9062481, DOI: 10.1210/jcem.82.3.3792.Peer-Reviewed Original ResearchConceptsProstate-specific antigenMarker of androgen excessSerum prostate-specific antigenHirsute womenReceiver operating characteristicAndrogen actionAndrogen excessLevels of prostate-specific antigenProstate-specific antigen levelProstate-specific antigen geneFemale serumAction of steroid hormone receptorsMarker of androgen actionAlpha-androstanediol glucuronideSerum PSA levelsFerriman-Gallwey scorePotential new markerSteroid hormone receptorsPSA levelsProstate-specificHyperandrogenic statePatient ageAlpha-androstanediolAlpha-AgBiochemical markersDetection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l
Yu H, Diamandis E, Wong P, Nam R, Trachtenberg J. Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l. Journal Of Urology 1997, 157: 913-918. PMID: 9072598, DOI: 10.1016/s0022-5347(01)65082-1.Peer-Reviewed Original ResearchConceptsProstate-specific antigenPositive surgical marginsPreoperative prostate-specific antigenSerum prostate-specific antigenSerial serum samplesBiochemical relapseSurgical marginsClinicopathological featuresRadical prostatectomyTumor volumeLogistic regression modelsPSA changeGreater preoperative prostate specific antigenPostoperative serum prostate-specific antigenHigher preoperative prostate-specific antigenPostoperative prostate-specific antigenUnconditional logistic regression modelsSerum samplesProstate-specific antigen monitoringSerum PSA changesSubset of patientsUnivariate logistic regression modelYear of surgeryLength of followupConventional prostate specific antigenDetection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l
Yu H, Diamandis E, Wong P, Nam R, Trachtenberg J. Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l. Journal Of Urology 1997, 157: 913-918.. DOI: 10.1097/00005392-199703000-00047.Peer-Reviewed Original ResearchProstate-specific antigenPositive surgical marginsPreoperative prostate-specific antigenSerum prostate-specific antigenSerial serum samplesBiochemical relapseMicro g.Clinicopathological featuresSurgical marginsRadical prostatectomyTumor volumeLogistic regression modelsPSA changeGreater preoperative prostate specific antigenPostoperative serum prostate-specific antigenHigher preoperative prostate-specific antigenPostoperative prostate-specific antigenUnconditional logistic regression modelsSerum samplesProstate-specific antigen monitoringSerum PSA changesUnivariate logistic regression modelYear of surgerySubset of patientsLength of followup
1996
Prostate-specific antigen in amniotic fluid of normal and abnormal pregnancies
Melegos D, Yu H, Allen L, Diamandis E. Prostate-specific antigen in amniotic fluid of normal and abnormal pregnancies. Clinical Biochemistry 1996, 29: 555-562. PMID: 8939403, DOI: 10.1016/s0009-9120(96)00093-8.Peer-Reviewed Original ResearchConceptsProstate-specific antigenSerum PSA concentrationAmniotic fluidPregnant womenFetal abnormalitiesPSA concentrationNonpregnant womenGestational ageHigher serum PSA concentrationsSerum prostate-specific antigenGestational week 15Gestational weeks 11Median PSA concentrationGestational weeks 13Gender of fetusesPSA levelsMaternal serumAbnormal pregnanciesMaternal ageRenal disordersLength of abstinenceWeek 13Week 15Diagnostic usefulnessTime-resolved immunofluorometric procedureProstate specific antigen — a new constituent of breast cyst fluid
Diamandis E, Yu H, López-Otín C. Prostate specific antigen — a new constituent of breast cyst fluid. Breast Cancer Research And Treatment 1996, 38: 259-264. PMID: 8739078, DOI: 10.1007/bf01806144.Peer-Reviewed Original ResearchConceptsProstate-specific antigenBreast cyst fluidCyst fluidSpecific antigenFree prostate-specific antigenBreast cystic diseasePSA presenceWestern blot analysisCystic diseaseBreast cancerNormal breastCutoff levelΑ1-antichymotrypsinMore studiesBlot analysisHigh-performance liquid chromatographyAntigenFrequent componentPerformance liquid chromatographySerine proteasesLiquid chromatographyCancerBreastDiseaseAssociations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer
Yu H, Levesque M, Khosravi M, Papanastasiou-Diamandi A, Clark G, Diamandis E. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. British Journal Of Cancer 1996, 74: 1242-1247. PMID: 8883411, PMCID: PMC2075943, DOI: 10.1038/bjc.1996.523.Peer-Reviewed Original ResearchConceptsInsulin-like growth factorProstate-specific antigenIGFBP-3IGF-IIBreast cancerS-phase fractionIGFBP-1Prognostic indicatorGrowth factorActive insulin-like growth factorsHER-2/neu proteinUnfavourable prognostic indicatorPrimary breast cancerEpidermal growth factor receptorSteroid hormone receptorsTumor tissue cytosolGrowth factor receptorIGF functionEstrogen receptorDNA ploidyPossible associationNeu proteinCancerTissue cytosolsHormone receptorsProstaglandin D2 synthase: a component of human amniotic fluid and its association with fetal abnormalities.
Melegos D, Yu H, Diamandis E. Prostaglandin D2 synthase: a component of human amniotic fluid and its association with fetal abnormalities. Clinical Chemistry 1996, 42: 1042-1050. PMID: 8674187, DOI: 10.1093/clinchem/42.7.1042.Peer-Reviewed Original ResearchConceptsProstate-specific antigenAmniotic fluidHuman amniotic fluidGestational week 12Western blot analysisAbnormal pregnanciesPGD2 synthaseStrong immunoreactive bandWeek 12Monoclonal anti-PSA antibodiesRenal abnormalitiesProstaglandin D2 synthaseTrisomic fetusesPGD2 productionFetal abnormalitiesAnti-PSA antibodiesImmunoreactive bandsBlot analysisSemiquantitative analysisFetusesAbnormalitiesPolyclonal antibodiesImmunoreactive speciesAntibodiesAmino acid sequence analysisProstate specific antigen in breast cancer, benign breast disease and normal breast tissue
Yu H, Diamandis E, Levesque M, Giai M, Roagna R, Ponzone R, Sismondi P, Monne M, Croce C. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Research And Treatment 1996, 40: 171-178. PMID: 8879683, DOI: 10.1007/bf01806212.Peer-Reviewed Original ResearchConceptsBenign breast diseaseProstate-specific antigenNormal breast tissueBreast diseaseBreast tumorsBreast tissueBreast cancerSpecific antigenBreast cancer tissuesSteroid hormone actionPSA positivityPSA levelsDisease stageProstatic adenocarcinomaPSA productionTumor markersStage IBBD tissueCancer tissuesFemale breastSteroid hormonesLow expressionPolymerase chain reaction amplificationTumorsChain reaction amplificationUltrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers.
Ferguson R, Yu H, Kalyvas M, Zammit S, Diamandis E. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clinical Chemistry 1996, 42: 675-684. PMID: 8653891, DOI: 10.1093/clinchem/42.5.675.Peer-Reviewed Original ResearchConceptsTime-resolved immunofluorometric assayProstate-specific antigenL PSAPotential applicationsUltrasensitive time-resolved immunofluorometric assayUltrasensitive detectionPSA immunoreactivityImmunofluorometric assayWide dynamic rangeFree prostate-specific antigenPostradical prostatectomy patientsEstrogen receptor positivityUltrasensitive PSA assaysDynamic rangePSA changeReceptor positivityProstatectomy patientsProstate cancerBreast cancerPSA assaysHook effectLow analytical limitsSignificant associationMonoclonal antibodiesSerum samples